Skip to content
Wenlo
Sign in
← Markets

Ionis Pharmaceuticals, Inc.

Shannon L. Devers (EVP, Chief Human Resources Ofc) sells IONS shares

4IONSFiled Oct 19, 2026, 5:40 PM ET· Period Oct 15, 2026

About this filing

Ionis Pharmaceuticals, Inc. (IONS) filed Form 4 (insider transaction) with the SEC on Oct 19, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Shannon L. Devers · EVP, Chief Human Resources Ofc
DateTransactionSharesPriceValueHeld afterOwnership
Oct 15, 2026M · exercise or conversion of a derivativeFootnotes F1+2,820$0.00$0.0019,168Direct
Oct 16, 2026S · open-market saleFootnotes F2, F3−1,357$43.54$59,081.8817,811Direct
Oct 15, 2026M · exercise or conversion of a derivativeRestricted Stock UnitFootnotes F4, F5−2,820$0.00$0.0049,884Direct
Footnotes
  1. F1 Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
  2. F2 The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
  3. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.1383 to $43.538918 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
  4. F4 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
  5. F5 Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

More IONS filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.